416 results about "Cholesterol lowering" patented technology

This invention relates to a method for prevention and treatment of aging, age-related disorders and / or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia and some forms of arthritis and cancer in a subject comprising administering to said subject, separately, sequentially or simultaneously a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor / antibody, interleukin-6 receptor inhibitor / antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor / antibody, tyrosine kinases inhibitors / antibodies, serine / threonine kinases inhibitors / antibodies, mitogen-activated protein (MAP) kinase inhibitors / antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors / antibodies, Nuclear factor κB (NF-κB) inhibitors / antibodies, IκB kinase (IKK) inhibitors / antibodies, activator protein-1 (AP-1) inhibitors / antibodies, STAT transcription factors inhibitors / antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging, age-related disorders and / or age-related manifestations including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor / antibody, interleukin-6 receptor inhibitor / antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor / antibody, tyrosine kinases inhibitors / antibodies, serine / threonine kinases inhibitors / antibodies, mitogen-activated protein (MAP) kinase inhibitors / antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors / antibodies, Nuclear factor κB (NF-κB) inhibitors / antibodies, IκB kinase (IKK) inhibitors / antibodies, activator protein-1 (AP-1) inhibitors / antibodies, STAT transcription factors inhibitors / antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and / or inhibition of the signal transduction pathway

This invention relates to a method for prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia and some forms of arthritis and cancer in a subject comprising administering to said subject, separately, sequentially or simultaneously a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor / antibody, interleukin-6 receptor inhibitor / antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor / antibody, tyrosine kinases inhibitors / antibodies, serine / threonine kinases inhibitors / antibodies, mitogen-activated protein (MAP) kinase inhibitors / antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors / antibodies, Nuclear factor κB (NF-κB) inhibitors / antibodies, IκB kinase (IKK) inhibitors / antibodies, activator protein-1 (AP-1) inhibitors / antibodies, STAT transcription factors inhibitors / antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging and age-related disorders including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor / antibody, interleukin-6 receptor inhibitor / antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor / antibody, tyrosine kinases inhibitors / antibodies, serine / threonine kinases inhibitors / antibodies, mitogen-activated protein (MAP) kinase inhibitors / antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors / antibodies, Nuclear factor κB (NF-κB) inhibitors / antibodies, IκB kinase (IKK) inhibitors / antibodies, activator protein-1 (AP-1) inhibitors / antibodies, STAT transcription factors inhibitors / antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and / or inhibition of the signal transduction pathway.

Disclosed here are effervescent granules having a controllable rate of effervescence. In some embodiments, the such granules comprise an acidic agent, an alkaline agent, a pharmacologically active agent, hot-melt extrudable binder capable of forming a eutectic mixture with the acidic agent and, optionally, a plasticizer. The effervescent granules are made by a hot-melt extrusion process. The present invention also provides a thermal heat process for preparing a pharmacologically active agent containing effervescent granule. In certain aspects, the granules contain pharmacologically active agents such as narcotics, antidiarrheal agents, antiviral agents, anxiolytic agents, a cholesterol lowering agent, an alpha adrenergic blocking agent, a phenanthrene derivative. By way of example, some of the narcotics that may be included in the granules and in the process of preparing the granules include, by way of example: phenanthrene derivatives (e.g., morphine sulfate), and morphine derivatives (e.g., hydromorphone hydrochloride).

Disclosed here are effervescent granules having a controllable rate of effervescence. In some embodiments, the such granules comprise an acidic agent, an alkaline agent, a pharmacologically active agent, hot-melt extrudable binder capable of forming a eutectic mixture with the acidic agent and, optionally, a plasticizer. The effervescent granules are made by a hot-melt extrusion process. The present invention also provides a thermal heat process for preparing a pharmacologically active agent containing effervescent granule. In certain aspects, the granules contain pharmacologically active agents such as narcotics, antidiarrheal agents, antiviral agents, anxiolytic agents, a cholesterol lowering agent, an alpha adrenergic blocking agent, a phenanthrene derivative. By way of example, some of the narcotics that may be included in the granules and in the process of preparing the granules include, by way of example: phenanthrene derivatives (e.g., morphine sulfate), and morphine derivatives (e.g., hydromorphone hydrochloride).

This invention relates to a method for prevention and treatment of Atherosclerosis, Peripheral Vascular Disease, Coronary Artery Disease, and age-related disorders including Osteoporosis, Arthritis, Type II Diabetes, Dementia and Alzheimer's disease in a subject comprising administering to said subject a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor / antibody, interleukin-6 receptor inhibitor / antibody, gp130 protein inhibitor / antibody, tyrosine kinases inhibitors / antibodies, STAT transcription factors inhibitors / antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging and age-related disorders including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway including interleukin-6 inhibitor / antibody, interleukin-6 receptor inhibitor / antibody, gp130 protein inhibitor / antibody, tyrosine kinases inhibitors / antibodies, STAT transcription factors inhibitors / antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and inhibition of the signal transduction pathway.

Antibody capable of mediating effector function which specifically binds to a multiple membrane spanning antigen or to an antigen which forms dimers or multimers (i) for use in combination with a cholesterol-increasing agent in the treatment of a disease or disorder associated with said antigen, wherein antibody-induced effector function has a beneficial effect on said disease or disorder or (ii) for use in the treatment of such disease or disorder, wherein the antibody is to be administered to a subject undergoing therapy with a cholesterol-lowering agent, such as a statin, and wherein the subject is withdrawn from treatment with the cholesterol-lowering agent prior to the administration of the antibody. Furthermore, a kit of parts comprising such antibody as well as a cholesterol-increasing agent.

A Lactobacillus plantarum BB9 capable of adhering to gastrointestinal tract and cholesterol removal is isolated from fruits and exhibits high BSH activity. In-vitro tests demonstrate that Lactobacillus plantarum BB9 has good acid and bile tolerance, and strong ability to adhere to intestinal cells. In-vivo tests show that hamsters fed high cholesterol diets added with BB9 strain have cholesterol and triglycerides in blood and liver effectively reduced, and their HDL-c / LDL-c ratios in blood are significantly higher than those of hamsters fed Lactobacillus acidophilus ATCC 43121 strain. It is hoped that the excellent acid and bile tolerance and intestinal adherence of the lactobacillus strain provided herein could produce cholesterol-lowering effect in humans.

A highly refined cellulose material is a composition of matter is used as an ingredient in the preparation of a neutraceutical in liquid, solid, or tablet form. These compositions may provide an expectation of a health benefit selected from the group consisting of Antioxidation; Cancer prevention; Arterial health improvement; Cholesterol lowering; Reduced blood pressure; Skin and wrinkle treatment; and Prolonging and / or delaying release of a nutrient into a bloodstream.

This invention relates to a method for prevention and treatment of Atherosclerosis, Peripheral Vascular Disease, Coronary Artery Disease, and age-related disorders including Osteoporosis, Arthritis, Type II Diabetes, Dementia and Alzheimer's disease in a subject comprising administering to said subject a therapeutically effective dosage of each component or combination of statins, bisphosphonates and / or cholesterol lowering agents or techniques, administered separately, in sequence or simultaneously. Cholesterol Metabolites (isoprenoids) are an integral component of the signaling pathway for Interleukin 6 mediated inflammation. Interleukin 6 inflammation is the common causative origin for Atherosclerosis, Peripheral Vascular Disease, Coronary Artery Disease, and age-related disorders including Osteoporosis, Arthritis, Type II Diabetes, Dementia and Alzheimer's disease. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism and isoprenoid depletion.

The invention provides a preparation method of leisure dried eggs. The technological process comprises the following steps: mixing and blending, condensing for forming, slicing, baking, marinating, cooling, packaging in vacuum, sterilizing at a high temperature and a high pressure, detecting metal, encoding and externally packaging. According to the preparation method, soyabean lecithin is added into the dried egg so that the accumulation of cholesterol in blood vessels can be alleviated; a baking process is improved on the basis of a common dried egg production process and the water content is adjusted; the appearance of the leisure dried eggs is improved and the shelf life of the leisure dried eggs is prolonged.

The present invention has its object to provide an antihypercholesterolemic or antihyperlipidemic agent, hence a therapeutic and prophylactic drug for arteriosclerosis, which is safer and more potent in cholesterol-lowering action than the hitherto-available drugs. A cholesterol-lowering composition comprising a coenzyme Q of the following formula (I) or a reduced coenzyme Q of the following formula (II) as an active ingredient: wherein n represents an integer of 6 to 11

Statin therapy has revolutionized the treatment of cardiovascular disease, but not all patients can take the appropriate level of statins because of their side effects. The present invention provides compositions that provide potent cholesterol lowering while minimizing the damaging side effects to liver, muscles, and neurons, and has the added benefit of reducing chronic systemic inflammation, which is an independent determinant of cardiovascular disease and all-cause mortality. The current invention presents pharmaceutical compositions for reducing cholesterol and chronic systemic inflammation comprising therapeutically effective amounts of: at least one lipid-lowering agent chosen from HMG-CoA reductase inhibitors, high-dose controlled-release niacin, red yeast rice, or policosanol; and at least one antiinflammatory natural product chosen from alpha-lipoic acid and corosolic acid. To those in need of such treatment, the current invention also provides safe methods for reducing high serum cholesterol or chronic inflammation, or for simultaneously reducing both cholesterol and chronic inflammation via treatment with therapeutically effective daily doses of pharmaceutical compositions as described herein. The present invention provides mammals with compositions and methods for concurrently reducing cholesterol and inflammation as a prevention or treatment for many age-related diseases and disorders.

The invention discloses an isoquinoline derivant. The said derivant, with 9,10-dimethoxy -[1,3] dioxide [4,5-g] isoquinoline [3,2-a] isoquinoline -7-ylidehydrochlorate (I) as its representative, reduces plasma cholesterol level by massively absorbing low density lipoprotein cholesterol and changing them to bile acid in liver. The 9,10-dimethoxy -[1,3] dioxide [4,5-g] isoquinoline [3,2-a] isoquinoline-7-ylidehydrochlorate is a new cholesterol lowering compound which is different in cholesterol lowering mechanism from statins. The 9,10-dimethoxy -[1,3] dioxide [4,5-g] isoquinoline [3,2-a] isoquinoline -7-ylidehydrochlorate and other isoquinoline derivants have an extremely low side toxiceffect, so they are safe natural cholesterol lowering compounds.

The present invention relates to a Kefiranofaciens subsp.kefiranofaciens ZW3 strain which is obtained from the Kefir grains through filtering separation and is preserved in Laboratory of culture collection of the Microbiology, Chinese Academy of Science. The preservation data is December 18, 2008, and the preserving number is CGMCC2809. The ZW3 strain of the invention has the advantages of excellent thermal stability, strong emulsifying capacity and high yield of exopolysaccharide. The exopolysaccharide which is obtained by separating and purifying the fermentation broth of the ZW3 strain is the macromolecule biological polysaccharides. The exopolysaccharide not only can be used as the thickening agent and the emulsifier in the food industry, but also can be used as the probiotics for promoting the growth of other probiotics in the intestional canal. The exopolysaccharide is also related with the functions of anti-tumor, anti-fistula, immunoregulation, cholesterol lowering or blood pressure regulating of the probiotics. Furthermore the exopolysaccharide has biodegradability and has no harm to the human body and the environment. The exopolysaccharide can be used as an effective flocculant in the food fields of wastewater treatment, drinking water product, downstream processing, etc.

The present invention is directed to nanoparticulate compositions comprising statin such as lovastatin or simvastatin. The statin particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of statins and other cholesterol lowering agents are described and methods of using same are taught.

The invention provides a composition and a method for lowering blood serum cholesterol levels or for preventing elevated blood serum cholesterol levels, as well as a suitable composition comprising (a) one or more phytosterols and / or phytostanols capable of reducing cholesterol absorption in the intestine and / or one or more soluble fibres capable of inhibiting ileal bile acid absorption, (b) a composition capable of inhibiting cholesterol biosynthesis, and (c) a composition capable of increasing cholesterol metabolism, wherein at least one of compositions (b) and (c) is preferably derived from plants.

The invention discloses weight reducing tea. The weight reducing tea is prepared from the following Chinese medicinal materials in parts by weight: 50 parts of black tea, 20 parts of cortex albiziae, 10 parts of Chinese date, 2 parts of isatis root, 2 parts of honeysuckle, 2 parts of dandelion, 2 parts of houttuynia cordata, 2 parts of selfheal, 2 parts of christina loosestrife herb, 2 parts of patrinia, 2 parts of Chinese pulsatilla root, 2 parts of folium isatidis, 2 parts of herba eupatorii and 2 parts of asarum. The weight reducing tea is safe and reliable, produces no damage or side effect to a digestive system and an absorption system of a human body, promotes normal metabolism of the human body by replenishing qi and blood and also has an effect of reducing cholesterol and blood fat and an obvious weight reducing effect, weight hardly can regain after the weight reducing tea is not drunk, and raw materials of the weight reducing tea are cheap and easily available, so that the weight reducing tea has the advantage of low cost and is applicable to market promotion.

A confectionery chew for lowering serum cholesterol in an animal in need thereof including a carbohydrate, a seeding agent, which can be a fondant, a structuring agent, which can be a protein, a starch, a hydrocolloid, and mixtures thereof, and cholesterol lowering agent selected from a sterol, a sterol ester, a stanol, a stanol ester, and mixtures thereof.

The invention relates to the use of pepper amide compound in preparation of drug or healthcare product for reducing blood fat with the general formula (I), wherein R, R1, R2 are defined in the specification, the piperamide compounds represented by formula (1) have the actions of substantially reducing cholesterin, triglyceride and increasing high density lipoprotein, fully activating lecithin cholesterol acyl transferase, forwarding extra-hepatic tissue cholesterol to liver, cleaning out plasma lipoproteins, plasma cholesterol and cholesterol esters, thus can be applied to the prevention and treatment of cardiovascular and cerebrovascular diseases, such as atherosclerotic, cerebrovascular, coronary artery and peribiliary vessel pathology and hyperlipemia.

The invention belongs to the technical field of dairy product processing, and particularly discloses a preparation method for high-activity peptide acidified milk. The method comprises the steps: S1, preparation of a leavening agent; S2, inoculation; S3, two-stage fermentation. According to the method, fermentation strains are screened and are compounded according to a certain ratio, and a two-stage fermentation method is adopted, so that the coordinate symbiosis among various strains gives full play to own characteristic advantages, the acid production, aroma producing and proteolysis capabilities of the strains tend to an optimal state, acidified milk obtained by production has more small molecule peptide than traditional acidophilus milk. Casein and whey protein are both subjected to advanced degradation during a fermentation process, so as to be easily digested and absorbed by a human body, the prepared high-activity peptide acidified milk has the healthcare functions of lowering serum cholesterol, reducing blood glucose, resisting hypertension, resisting oxidation, boosting immunity, improving intestinal function, and the like.

Stanol compound containing compositions containing a cholesterol reducing effective amount of at least one stanol compound which is an effective way of ingesting the stanol compounds to achieve the desired cholesterol reducing effect.

The invention relates to the technical field of soybean deep processing and specifically discloses a low-molecular soybean peptide and a preparation method thereof. The preparation method for preparing the low-molecular soybean peptide comprises the following steps: taking soy isolate protein and adding the soy isolate protein into RO pure water under the temperature of 20-45 DEG C, adjusting pH value to 5-9 and acquiring a solution 1; under the temperature of 40-70 DEG C, adding compound protease in steps into the solution 1, stirring and performing enzymolysis for 3-5 hours, thereby acquiring a solution 2; keeping the temperature of the solution 2 for 10-30min under the temperature of 70-95 DEG C, performing membrane treatment under the temperature of 40-70 DEG C and filtering the matters with molecular weight of 150-2000Da, thereby acquiring a solution 3; performing nanofiltration treatment on the solution 3 at normal temperature, intercepting the matters with the molecular weight of 150-300DDa, thereby acquiring a solution 4; and sterilizing the solution 4 and performing spray drying treatment, thereby acquiring the low-molecular soybean peptide. The soybean peptide is low in molecular weight, is concentrated and has the effects of oxidation resistance, blood pressure reduction, blood fat reduction and cholesterol reduction.

The invention discloses a strain of streptococcus thermophilus capable of lowering cholesterol levels. The streptococcus thermophilus has a classification name of streptococcus thermophilus BLST, and was collected in China Center for Type Culture Collection with the collection number of CCTCC NO.M 2012282 on July 11th, 2012. Tests prove that the streptococcus thermophilus has a cholesterol lowering function, so that the bacterial strain of the streptococcus thermophilus can be used as medicine or dietary supplements or be used in preparation of medicine or dietary supplements. During specific application, the streptococcus thermophilus BLST can be cultured, and thus fermentation products, namely the dietary supplements for lowering the cholesterol levels, are obtained. The fermentation products can also serve as raw materials of the medicine or the dietary supplements for lowering the cholesterol levels. The invention also provides a streptococcus thermophilus preparation named Baiao Zhile capable of lowering cholesterol levels, and the preparation consists of the following raw materials: hawthorn fruit, ganoderma lucidum spores powder, red kojic rice powder, fructooligosaccharide, xylooligosaccharide, streptococcus thermophilus BLST powder and lactobacillus plantarum LP-11 powder.

The invention relates to a balsam pear beverage and a preparation method thereof. The balsam pear beverage is fermented by balsam pear juice, syrup or substituted sugar, purified water and lactobacillus. The balsam pear beverage prepared through the method has the advantages of being sweet, sour and pure in taste without bitter, good in aftertaste and nutrition, high in functionality, and capable of reducing blood sugar and cholesterol, regulating blood liquid, improving intestinal microecological balance of human bodies, and increasing immunity of the human bodies. Additionally, by aid of the fermentation of the lactobacillus, amino acid content in the balsam pear beverage can be improved by more than 10%, flavor substance content can be improved by more than 30%, therefore the flavor and taste of the products can be effectively improved, nutritional components such as vitamins in the balsam pears are fully maintained, and the service life is prolonged.

The invention relates to a self-screened Lactobacillus acidophilus SJLH001 (La SJLH001 for short) with probiotic function of regulating blood sugar and cholesterol level and application thereof in probiotic food. The strain has good tolerance to gastrointestinal environment, and has antioxidant, hydrophobic, ultrasonic resistance, reducing power and other in vitro benefits. In vitro and in vivo functional tests showed that La-SJLH001 has significant amylase inhibitory activity and alpha-Glucose glycerase inhibitory activity, and can significantly reduce fasting blood glucose, postprandial blood glucose level, enhance the tolerance of glucose, alleviate the pancreatic islet enlargement, reduce serum cholesterol level, enhance intestinal mucosal protection and other functions. La- SJLH001 has significant hypoglycemic and cholesterol-lowering activities, which makes it widely used in various forms of probiotic foods (such as probiotic tablet candy, probiotic solid drinks, etc.).

The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount.The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.

An apiin derivative, its production, medicinal composition containing it and its usage in treatment of diabetes and its complication are disclosed. It can also be used to prepare hypoglycemic, hypolipidemic and cholesterol-lowering medicines with aldose reductase activity inhibiting function.

The invention discloses a cholesterol-lowering ferment cultured milk and a preparation method thereof. The material milk is prepared by fermenting 3 mixing strains of the lactobacillus GL-03, bulgaria bacillus and streptococcus thermophilus, and a hawthorn extract; the technique comprises the following steps: the material milk is needed for milk-test and purifying, and then can be prepared for use, sucrose and a stabilizing agent are dissolved by little solution, and then added in the milk liquid after purifying; the temperature is enhancedto 60 DEG C for carrying out homogenate, sterilization, the temperature is lowered down to 43 DEG C, inoculation is carried out in a greenhouse of 40-45 DEG C for fermenting 4-5 hours, the temperature is cooled to under 10 DEG C after the pH value is 4.6-4.8, then the ferment cultured milk is done after being replaced to a refrigeratory of 0-4 DEG C for refrigeration. Shown by GL-03 culture in vitro test, the ferment cultured milk has strong acid and cholate resistant ability, good adhesive, obvious inhibit to common pathogenic entero becteria, without drug tolerance factors, is a lactobacillus applicable to permanent planting of human body intestinal tract, and simultaneously the deterioration ratio of the cholesterol in vitro can be up to 56 percent; proved by the animal-test, the cholesterol-lowering cultured milk has the function of lowering serum cholesterol.